AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05641532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavioral intervention in persons newly diagnosed with MS
Description: 1. The newsletters will provide the knowledge, skills, resources, and strategies for promoting physical activity in persons newly diagnosed with MS. These newsletters will be released seven times during the program. The first three newsletters will be released weekly, and the last four will be released every other week.~2. The one-on-one video coaching chats with participants will be conducted via Zoom, which consist of discussion and elaboration of newsletters content, supportive accountability, feedback and encouragement on behavior change. The chats further provide social persuasion for promoting behavior change. The chats are semi-scripted and individualized interventions (\~15 - 30 minutes/chat). The chats will occur seven times during the week when a newsletter is delivered.~3. The intervention includes a pedometer (NL-800 pedometer), a logbook, and a calendar for tracking daily step counts, planning of physical activity, setting goals, and monitoring progress over the program.
Study NCT05619458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: 6-week mindfulness intervention
Study NCT05611073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Measurement of distance, intermediate and near visual acuity.
Study NCT05611073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biometric Data Collection
Description: Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
Study NCT05611073 — intervention group
Intervention type: OTHER
Intervention: Patient Questionnaire
Description: Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
Study NCT05585866 — intervention group
Intervention type: DRUG
Intervention: Anesthesia Agent
Description: The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
Study NCT04362891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cosmetic lip augmentation
Description: The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.
Study NCT04059965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panel Management for Anticoagulation Therapy
Description: Patients in the intervention arm will receive notifications reminding them of upcoming labs and appointments. We hypothesize this will improve adherence and therapeutic control and reduce risk for bleeds and/or strokes
Study NCT04059965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will receive standard, protocolized care in their respective anticoagulation clinics
Study NCT06231147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HORSE RIDING SIMULATOR WITH VISUAL FEEDBACK
Description: horse riding simulator session with mirror visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system in front of mirror
Study NCT06231147 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HORSE RIDING SIMULATOR WITHOUT VISUAL FEEDBACK
Description: horse riding simulator session without visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system.
Study NCT05214560 — intervention group
Intervention type: DEVICE
Intervention: Spinal needle
Description: Insertion of a spinal needle to perform the neuraxial procedure.
Study NCT03764748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation
Description: The prepared microbiota suspension was infused into the participates' lower gut.
Study NCT05003635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVEBRA device
Description: Wear 2 weeks pre-operatively for a total duration of 200 hours. Wear 2 weeks post-operatively for 10 hours a day.
Study NCT05607238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Vascular Access - Midline catheter
Description: Ultrasound guided vascular access with a midline IV catheter
Study NCT05607238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Vascular Access - peripheral IV
Description: Ultrasound guided vascular access with a peripheral IV catheter
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study NCT04786067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
Study NCT04831060 — intervention group
Intervention type: PROCEDURE
Intervention: Periodontal treatment
Description: For Cases :~* Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~* Non-surgical periodontal treatment~* At 3 months = periodontal reevaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~* If periodontal pockets greater than 5mm and bleeding persist: periodontal surgery and gingival explant sampling~* At 3 months post-surgery = periodontal re-evaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~* Maintenance~For Controls:~* Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~* Plastic or pre-prosthetic surgery = gingival explant sampling~* Healing control at 15 days
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: Pharmaceutical form:Oral solution-Route of administration:Oral
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella virus vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular
Study NCT06397768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
Study NCT04181736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Tablets
Description: Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
Study NCT05736029 — intervention group
Intervention type: OTHER
Intervention: blood, stool and tissue samples collection
Description: blood, stool and tissue samples collection before and during the treatment, as applicable
Study NCT06219798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GFR
Description: Exit of the study due to death, dialysis, or transplantation
Study NCT06151561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: Intramuscular Injection
Study NCT06151561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection
Study NCT05673538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00973-MS tablets treatment
Description: The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
Study NCT04810702 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04361266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotium nanoscaffold
Description: Rotium bioabsorbable nanoscaffold placed between bone-tendon interface of rotator cuff repair construct
Study NCT04361266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control arm rotator cuff repair
Description: Standard rotator cuff repair without Rotium
Study NCT05717257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
Study NCT05791435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PneuRIP
Description: Measuring respiratory indices through Respiratory Inductance Plethysmography
Study NCT05791435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biofeedback to assist with breathing
Description: Measuring respiratory indices through Respiratory Inductance Plethysmography and providing visual biofeedback on a tablet screen
Study NCT05847062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse shoulder arthroplasty
Description: The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.
Study NCT05420805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ALAC, inulin, FOS, and sodium butyrate
Description: Pre- and post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
Study NCT05420805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium butyrate and zinc oxide
Description: Post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization, as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
Study NCT06588478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.
Study NCT06588478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirtobrutinib
Description: Administered Orally.
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg per kilogram of body weight enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4mg, enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg subcutaneously once daily for 10 days (or hospital discharge pending which will occur first) (same for adults and children)
Study NCT06679530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindful Music Listening (MML)
Description: Self-guided mindful music listening intervention comprised of 1-hour daily music listening during inpatient hospitalization.
Study NCT05675332 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Task-based behavioral intervention
Description: Brief behavioral intervention is absent of stressors.
Study NCT05675332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-based behavioral intervention
Description: Brief behavioral intervention involves interacting with common everyday types of stress.
Study NCT04535843 — intervention group
Intervention type: DEVICE
Intervention: pheripheral biomarkers or omics data
Description: To detect pheripheral biomarkers and omics data,including lymphocytes and cytokines, in this prospective MG cohort.
Study NCT06284538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NOVA.EMOSTOP RE-EPITHELIZING
Description: RE-EPITHELIZING GEL BASED ON HYALURONIC ACID
Study NCT06284538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVA.EMOSTOP RE-EPITHELIZING
Description: RE-EPITHELIZING GEL BASED ON HYALURONIC ACID
Study NCT05999006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELIOS Procedure
Description: Treatment with the ELIOS System
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 50mg (in children: 1-2 mg/kg) IV Q6 for 7 days
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and fludrocortisone
Description: Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanThrombomodulin( rhTM)
Description: Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).
Study NCT06381661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat
Description: 0.2 mg/kg/h for 7 days (or ICU discharge, pending which will occur first)
Study NCT06381661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Description: 12 ml/kg/day as long as INR remains >1.4
Study NCT06381661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT05293847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercises and postural skills
Description: 12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
Study NCT04709627 — intervention group
Intervention type: DEVICE
Intervention: enFlow IV Fluid and Blood Warming System
Description: The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
Study NCT05630963 — intervention group
Intervention type: DEVICE
Intervention: Aversive stimuli
Description: Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
Study NCT05630963 — intervention group
Intervention type: DRUG
Intervention: PET radiotracer
Description: A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels.
Study NCT05358132 — intervention group
Intervention type: DEVICE
Intervention: Pneumowave Device placement and data capture
Description: Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,
Study NCT05876403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: The participants of controlled group will be given the treatment protocol after baseline measurements controlled breathing techniques (3session per week 10mins for 6 weeks) \& Aerobic exercise(3 session per week for 6 weeks) with 10sec hold into 10reps.outcome measures will be recorded through a digital spirometer \& measurement of 6MWT \& chest expansion.
Study NCT05876403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: The participants of experimental group will be given the Intervention protocol after baseline measurements. Additionally these 30 participants will also receive PNF technique exercises consisting of Thoracic Vertebral pressure, Anterior Basal stretch, and Intercostal stretch for 20-25 minutes in 3 sessions per week, and outcomes Measures will be recorded through a digital spirometer and measurements of 6 minutes walk test and chest Expansion.
Study NCT05158855 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis spore extract
Description: Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.
Study NCT05463653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental
Description: A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery
Study NCT05463653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery
Study NCT05506462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
Study NCT04772326 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire
Study NCT04756336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 gel, 3% w/w
Description: The drug is applied to affected lesions according to treatment regimen
Study NCT04588103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Lower limb warm water immersion (42 degrees C)
Study NCT04588103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Moderate-intensity cycling exercise (\~40-59% VO2 reserve)